Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYTK Cytokinetics	$36.69 -2.5%	$34.41	$29.31 ▼ $59.39	$4.50B	0.64	1.28 million shs	1.09 million shs
MRUS Merus	$65.56 -1.0%	$56.89	$33.19 ▼ $67.59	$4.58B	1.09	679,176 shs	664,677 shs
PAHC Phibro Animal Health	$26.11 -1.5%	$26.70	$16.16 ▼ $31.80	$1.07B	0.8	303,453 shs	356,504 shs
PCVX Vaxcyte	$33.02 -2.7%	$34.44	$27.66 ▼ $121.06	$4.38B	1.21	1.17 million shs	1.11 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYTK Cytokinetics	-2.52%	-1.32%	+6.78%	-1.77%	-37.82%
MRUS Merus	-1.03%	-1.89%	+22.93%	+48.36%	+23.60%
PAHC Phibro Animal Health	-1.47%	-10.52%	-6.55%	+34.03%	+38.29%
PCVX Vaxcyte	-2.74%	-9.86%	-0.75%	-6.70%	-58.14%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CYTK Cytokinetics	4.0154 of 5 stars	4.4	1.0	0.0	4.6	2.6	0.8	0.0
MRUS Merus	2.6948 of 5 stars	3.5	4.0	0.0	0.0	1.9	2.5	0.0
PAHC Phibro Animal Health	4.1278 of 5 stars	0.9	5.0	2.5	1.1	3.4	3.3	2.5
PCVX Vaxcyte	2.2402 of 5 stars	3.6	2.0	0.0	0.0	3.0	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CYTK Cytokinetics	2.88	Moderate Buy	$70.92	93.30% Upside
MRUS Merus	3.00	Buy	$86.40	31.79% Upside
PAHC Phibro Animal Health	1.83	Reduce	$24.40	-6.55% Downside
PCVX Vaxcyte	3.10	Buy	$136.50	313.39% Upside

Current Analyst Ratings Breakdown

Latest PAHC, PCVX, MRUS, and CYTK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/30/2025	CYTK Cytokinetics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Perform
7/7/2025	PAHC Phibro Animal Health	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$25.00 ➝ $35.00
6/25/2025	PAHC Phibro Animal Health	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$21.00 ➝ $26.00
6/16/2025	PAHC Phibro Animal Health	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
6/16/2025	PAHC Phibro Animal Health	BNP Paribas Exane Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underperform ➝ Neutral	$24.00
6/9/2025	CYTK Cytokinetics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$71.00 ➝ $53.00
5/29/2025	CYTK Cytokinetics	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$103.00 ➝ $84.00
5/23/2025	MRUS Merus	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$96.00 ➝ $110.00
5/19/2025	MRUS Merus	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00 ➝ $75.00
5/14/2025	CYTK Cytokinetics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$72.00 ➝ $72.00
5/13/2025	CYTK Cytokinetics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CYTK Cytokinetics	$18.47M	237.24	N/A	N/A	($1.15) per share	-31.90
MRUS Merus	$36.13M	125.59	N/A	N/A	$9.46 per share	6.93
PAHC Phibro Animal Health	$1.02B	1.04	$2.08 per share	12.54	$6.34 per share	4.12
PCVX Vaxcyte	N/A	N/A	N/A	N/A	$26.52 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CYTK Cytokinetics	-$589.53M	-$5.29	N/A	N/A	N/A	-3,201.47%	N/A	-43.75%	8/7/2025 (Estimated)
MRUS Merus	-$215.33M	-$4.08	N/A	N/A	N/A	-506.73%	-35.99%	-29.83%	8/7/2025 (Estimated)
PAHC Phibro Animal Health	$2.42M	$0.78	33.47	12.43	0.44	2.68%	30.51%	6.89%	8/27/2025 (Estimated)
PCVX Vaxcyte	-$463.93M	-$3.99	N/A	N/A	N/A	N/A	-17.12%	-16.26%	8/5/2025 (Estimated)

Latest PAHC, PCVX, MRUS, and CYTK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/27/2025	Q4 2025	PAHC Phibro Animal Health	$0.52	N/A	N/A	N/A	$362.24 million	N/A
8/7/2025	Q2 2025	CYTK Cytokinetics	-$1.32	N/A	N/A	N/A	$1.95 million	N/A
8/7/2025	Q1 2025	MRUS Merus	-$1.17	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	PCVX Vaxcyte	-$1.12	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	MRUS Merus	-$1.17	-$1.40	-$0.23	-$1.40	$7.82 million	$26.49 million
5/14/2025	Q1 2025	PCVX Vaxcyte	-$1.02	-$1.04	-$0.02	-$1.04	N/A	N/A
5/7/2025	Q3 2025	PAHC Phibro Animal Health	$0.52	$0.63	+$0.11	$0.51	$352.41 million	$347.80 million
5/6/2025	Q1 2025	CYTK Cytokinetics	-$1.41	-$1.36	+$0.05	-$1.36	$2.77 million	$1.60 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CYTK Cytokinetics	N/A	N/A	N/A	N/A	N/A
MRUS Merus	N/A	N/A	N/A	N/A	N/A
PAHC Phibro Animal Health	$0.48	1.84%	N/A	61.54%	N/A
PCVX Vaxcyte	N/A	N/A	N/A	N/A	N/A

Latest PAHC, PCVX, MRUS, and CYTK Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/29/2025	PAHC Phibro Animal Health	quarterly	$0.12	1.71%	9/3/2025	9/3/2025	9/24/2025
5/6/2025	PAHC Phibro Animal Health	quarterly	$0.12	2.52%	6/4/2025	6/4/2025	6/25/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CYTK Cytokinetics	N/A	5.99	5.99
MRUS Merus	N/A	5.86	5.86
PAHC Phibro Animal Health	2.67	2.91	1.23
PCVX Vaxcyte	N/A	17.70	17.70

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CYTK Cytokinetics	N/A
MRUS Merus	96.14%
PAHC Phibro Animal Health	99.34%
PCVX Vaxcyte	96.78%

Insider Ownership

Company	Insider Ownership
CYTK Cytokinetics	2.70%
MRUS Merus	4.57%
PAHC Phibro Animal Health	50.07%
PCVX Vaxcyte	3.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CYTK Cytokinetics	250	119.43 million	116.20 million	Optionable
MRUS Merus	37	69.21 million	66.05 million	Optionable
PAHC Phibro Animal Health	1,940	40.53 million	20.24 million	Optionable
PCVX Vaxcyte	160	129.00 million	125.01 million	Optionable

PAHC, PCVX, MRUS, and CYTK Headlines

Recent News About These Companies

Vaxcyte, Inc. (PCVX)’s VAX-24 Achieves Phase 2 Success in Infants

July 31 at 11:49 AM | finance.yahoo.com

Vaxcyte, Inc. (PCVX)’s VAX-24 Achieves Phase 2 Success in Infants

July 31 at 11:49 AM | insidermonkey.com

Vaxcyte, Inc. (NASDAQ:PCVX) Shares Sold by TD Asset Management Inc

July 31 at 5:01 AM | marketbeat.com

Fiera Capital Corp Invests $13.56 Million in Vaxcyte, Inc. (NASDAQ:PCVX)

July 30 at 4:11 AM | marketbeat.com

Skandinaviska Enskilda Banken AB publ Acquires New Position in Vaxcyte, Inc. (NASDAQ:PCVX)

July 30 at 4:11 AM | marketbeat.com

Vaxcyte, Inc. (NASDAQ:PCVX) Receives $136.50 Average PT from Analysts

July 30 at 3:11 AM | americanbankingnews.com

Vaxcyte (PCVX) Projected to Post Earnings on Tuesday

July 29, 2025 | marketbeat.com

Vaxcyte, Inc. (NASDAQ:PCVX) Stake Lifted by Envestnet Asset Management Inc.

July 27, 2025 | marketbeat.com

Teachers Retirement System of The State of Kentucky Acquires 6,929 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

July 26, 2025 | marketbeat.com

Vaxcyte, Inc. (NASDAQ:PCVX) Receives Consensus Recommendation of "Buy" from Analysts

July 25, 2025 | marketbeat.com

Victory Capital Management Inc. Has $8.34 Million Stock Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)

July 25, 2025 | marketbeat.com

New York State Common Retirement Fund Increases Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)

July 22, 2025 | marketbeat.com

Jennison Associates LLC Has $42.51 Million Stock Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)

July 20, 2025 | marketbeat.com

C WorldWide Group Holding A S Makes New $3.59 Million Investment in Vaxcyte, Inc. (NASDAQ:PCVX)

July 18, 2025 | marketbeat.com

Mizuho Maintains an Overweight Rating on Vaxcyte (PCVX)

July 16, 2025 | insidermonkey.com

Vaxcyte, Inc. (NASDAQ:PCVX) Shares Sold by TimesSquare Capital Management LLC

July 15, 2025 | marketbeat.com

Principal Financial Group Inc. Has $17.73 Million Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)

July 11, 2025 | marketbeat.com

Brown Advisory Inc. Acquires 14,049 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

July 10, 2025 | marketbeat.com

Allspring Global Investments Holdings LLC Lowers Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)

July 4, 2025 | marketbeat.com

Cantor Fitzgerald Maintains Overweight on Vaxcyte Amid Vaccine Development and ACIP Meeting

July 2, 2025 | msn.com

86,244 Shares in Vaxcyte, Inc. (NASDAQ:PCVX) Acquired by Peregrine Capital Management LLC

July 2, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PAHC, PCVX, MRUS, and CYTK Company Descriptions

Cytokinetics NASDAQ:CYTK

$36.69 -0.95 (-2.52%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$36.92 +0.23 (+0.64%)

As of 08/1/2025 04:20 PM Eastern

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Merus NASDAQ:MRUS

$65.56 -0.68 (-1.03%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$65.50 -0.06 (-0.08%)

As of 08/1/2025 05:53 PM Eastern

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Phibro Animal Health NASDAQ:PAHC

$26.11 -0.39 (-1.47%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$26.12 +0.02 (+0.06%)

As of 08/1/2025 04:32 PM Eastern

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

Vaxcyte NASDAQ:PCVX

$33.02 -0.93 (-2.74%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$32.91 -0.11 (-0.33%)

As of 08/1/2025 04:55 PM Eastern

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time